Back to Search Start Over

Adenosine Diphosphate Improves Wound Healing in Diabetic Mice Through P2Y12 Receptor Activation.

Authors :
Borges, Paula Alvarenga
Waclawiak, Ingrid
Georgii, Janaína Lima
Fraga-Junior, Vanderlei da Silva
Barros, Janaína Figueiredo
Lemos, Felipe Simões
Russo-Abrahão, Thaís
Saraiva, Elvira Maria
Takiya, Christina M.
Coutinho-Silva, Robson
Penido, Carmen
Mermelstein, Claudia
Meyer-Fernandes, José Roberto
Canto, Fábio B.
Neves, Josiane Sabbadini
Melo, Paulo A.
Canetti, Claudio
Benjamim, Claudia Farias
Source :
Frontiers in Immunology; 03/22/2021, Vol. 11, pN.PAG-N.PAG, 18p
Publication Year :
2021

Abstract

Chronic wounds are a public health problem worldwide, especially those related to diabetes. Besides being an enormous burden to patients, it challenges wound care professionals and causes a great financial cost to health system. Considering the absence of effective treatments for chronic wounds, our aim was to better understand the pathophysiology of tissue repair in diabetes in order to find alternative strategies to accelerate wound healing. Nucleotides have been described as extracellular signaling molecules in different inflammatory processes, including tissue repair. Adenosine-5'-diphosphate (ADP) plays important roles in vascular and cellular response and is immediately released after tissue injury, mainly from platelets. However, despite the well described effect on platelet aggregation during inflammation and injury, little is known about the role of ADP on the multiple steps of tissue repair, particularly in skin wounds. Therefore, we used the full-thickness excisional wound model to evaluate the effect of local ADP application in wounds of diabetic mice. ADP accelerated cutaneous wound healing, improved new tissue formation, and increased both collagen deposition and transforming growth factor-β (TGF-β) production in the wound. These effects were mediated by P2Y<subscript>12</subscript> receptor activation since they were inhibited by Clopidogrel (Clop) treatment, a P2Y<subscript>12</subscript> receptor antagonist. Furthermore, P2Y<subscript>1</subscript> receptor antagonist also blocked ADP-induced wound closure until day 7, suggesting its involvement early in repair process. Interestingly, ADP treatment increased the expression of P2Y<subscript>12</subscript> and P2Y<subscript>1</subscript> receptors in the wound. In parallel, ADP reduced reactive oxygen species (ROS) formation and tumor necrosis factor-α (TNF-α) levels, while increased IL-13 levels in the skin. Also, ADP increased the counts of neutrophils, eosinophils, mast cells, and gamma delta (γδ) T cells (Vγ4<superscript>+</superscript> and Vγ5<superscript>+</superscript> cells subtypes of γδ<superscript>+</superscript> T cells), although reduced regulatory T (Tregs) cells in the lesion. In accordance, ADP increased fibroblast proliferation and migration, myofibroblast differentiation, and keratinocyte proliferation. In conclusion, we provide strong evidence that ADP acts as a pro-resolution mediator in diabetes-associated skin wounds and is a promising intervention target for this worldwide problem. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16643224
Volume :
11
Database :
Complementary Index
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
149413866
Full Text :
https://doi.org/10.3389/fimmu.2021.651740